Principal Investigators

    Professor Nick Fox


    Institute of Neurology, University College London

    Contact information of lead PI


    United Kingdom

    Title of project or programme

    Improving prevention trials in Alzheimer’s disease through imaging

    Source of funding information

    Alzheimer's Society

    Total sum awarded (Euro)

    € 338,903

    Start date of award


    Total duration of award in years



    Research Abstract

    There is increasing interest in secondary prevention therapeutic trials
    in Alzheimer’s disease (AD). These studies will enrol asymptomatic
    individuals at high risk of AD by virtue of their family history, genetic
    status or evidence of cerebral amyloid deposition and incorporate
    imaging and fluid biomarkers. They urgently need more evidence to
    support the most effective use of these markers.
    We will analyse imaging and other data from the Dominantly Inherited
    Alzheimer’s Network (DIAN) study and use these findings to provide
    an evidence-base to inform prevention trials. DIAN participants are
    studied longitudinally with serial clinical, neuro-psychometric, and
    CSF-based measures as well as comprehensive imaging including
    amyloid PET and MR (structural, diffusion and functional) imaging.
    DIAN has recruited individuals for over six years from 13 centres and
    will make available multiple time point assessments from ~200
    We will optimise the pre-processing and analysis methods for the
    imaging modalities including intra-subject and inter-modality
    registration; we will assess the use of these derived measures for
    inclusion and end-point purposes; we will compute means and
    variances for rates of change for each of the different outcomes; we
    will assess composite end-points; we will model different trial design
    scenarios using these and other inclusion/outcome approaches.
    We will determine sample sizes required to provide appropriate
    statistical power for a range of potential trial scenarios and determine
    the impact of different inclusion criteria, trial enrichment, follow-up
    duration, and the benefits of using run-in designs. Ultimately we aim
    to enhance and guide future prevention trials.

    Further information available at:

Types: Investments < €500k
Member States: United Kingdom
Diseases: N/A
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF